title: Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain.
abstract: METHODS
  Open, randomized, parallel group multicenter study.
  
  
  OBJECTIVE
  To compare the efficacy and safety of transdermal fentanyl (TDF) and sustained release morphine (SRM) in strong-opioid naïve patients with chronic low back pain (CLBP).
  
  
  BACKGROUND
  Most studies of TDF and SRM have involved patients already receiving strong opioids. This is the first large-scale study focusing on strong-opioid naïve patients with CLBP.
  
  
  METHODS
  Adults with CLBP requiring regular strong opioid therapy received either TDF or SRM for 13 months. Starting doses were 25 microg/hr fentanyl patches every 72 hours or 30 mg oral morphine every 12 hours. Doses were adjusted according to response. Participants assessed pain relief and bowel function using weekly diaries. Other assessments, including quality of life, disease progression, and side effects, were made by patients and investigators.
  
  
  RESULTS
  Data from 680 patients showed that TDF and SRM provided similar levels of pain relief, but TDF was associated with significantly less constipation than SRM, indicating a greater likelihood of satisfactory pain relief without unmanageable constipation for patients receiving TDF. Other ratings were similar for TDF and SRM, but TDF provided greater relief of pain at rest and at night.
  
  
  CONCLUSIONS
  TDF and SRM provided equivalent levels of pain relief, but TDF was associated with less constipation. This study indicates that sustained-release strong opioids can safely be used in strong-opioid naïve patients.
authors.affiliation: Northwick Park & St. Marks NHS Trust, Harrow, Middlesex, UK. laurie.allan@datacam.net
authors.forename: Laurie
authors.initials: L
authors.lastname: Allan
authors.forename: Ute
authors.initials: U
authors.lastname: Richarz
authors.forename: Karen
authors.initials: K
authors.lastname: Simpson
authors.forename: Robert
authors.initials: R
authors.lastname: Slappendel
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects; D002908:Chronic Disease; D003248:Constipation / Q000139:chemically induced; D003692:Delayed-Action Preparations; D018450:Disease Progression; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D017116:Low Back Pain / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage* / Q000009:adverse effects; D011788:Quality of Life; D018582:Sick Leave; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D009020:Morphine; D005283:Fentanyl